Saturday - June 13, 2026

Category Archives: Financial Market

Crest Operating Partners Releases Landmark Public Report on Specialty and Gluten-Free Baked Goods Growth

Crest Operating Partners releases “Specialty & Gluten-Free Growth Trends,” a comprehensive market overview analyzing consumer demand shifts, wellness-driven purchasing behavior, specialty ingredient innovation, and growth opportunities across the global bakery industry. New research synthesis by Crest Operating Partners reveals a … Continue reading →

StudentEB5 Publishes Part Two of EB-5 Filing Guide: Attorney Selection, Full Cost Breakdown, and Answers to the Most Common Investor Questions

StudentEB5 has published Part Two of its EB-5 filing guide for H-1B professionals and international students. The installment covers attorney selection, a full cost breakdown totaling roughly $886,000 to $911,000 including the core investment, and answers to the most common … Continue reading →

New Free Tool Helps Investors Compare Gold IRA Custodian Fees Across Top Providers

Chart comparing gold IRA custodian fees across multiple providers with annual and flat-rate fee structures. GoldIRAFeesCalculator.com releases a calculator that compares gold IRA custodian fees, giving retirement investors the transparency they need to maximize long-term returns. Choosing the right custodian … Continue reading →

StudentEB5 Publishes Step-by-Step EB-5 Filing Guide for Backlogged H-1B Professionals and International Students

StudentEB5 has published a step-by-step EB-5 filing guide for H-1B professionals and international students. The guide covers accredited investor eligibility, source of funds documentation requirements, and a five-point framework for regional center and project selection including rural TEA priority processing, … Continue reading →

IGC Pharma (NYSE American: IGC) Alzheimer’s Drug Gains Attention After Ascendiant Capital Raises Price Target

  IGC Pharma, Inc. (NYSE: IGC), a clinical-stage biotechnology company focused on Alzheimer’s disease, artificial intelligence, and drug discovery, is drawing renewed investor attention after Ascendiant Capital reiterated its BUY rating and increased its 12-month price target to $5.50, citing … Continue reading →